Quick Answer
Moderna, Inc. reported Total Revenue of $1.94 billion for fiscal year 2025.
Moderna, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.94B -39.9% |
$3.24B -52.7% |
$6.85B -64.4% |
$19.26B +4.3% |
$18.47B +2200.2% |
$803.00M +1238.3% |
| Revenue (ASC 606) | $1.94B -39.9% |
$3.24B -52.7% |
$6.85B -64.4% |
$19.26B +4.3% |
$18.47B | — |
| Net Income | -$2.82B +20.8% |
-$3.56B +24.5% |
-$4.71B -156.4% |
$8.36B -31.5% |
$12.20B +1733.5% |
-$747.00M -45.3% |
| Diluted EPS | -$7.26 +21.8% |
-$9.28 +24.7% |
-$12.33 -161.3% |
$20.12 -28.9% |
$28.29 +1543.4% |
-$1.96 -26.5% |
| Total Assets | $12.34B -12.8% |
$14.14B -23.2% |
$18.43B -28.7% |
$25.86B +4.8% |
$24.67B +236.2% |
$7.34B +361.6% |
| Cash and Equivalents | $2.60B +34.7% |
$1.93B -33.7% |
$2.91B -9.3% |
$3.21B -53.2% |
$6.85B +161.0% |
$2.62B +1011.9% |
| Long-Term Debt | $590.00M | $0.00 | — | — | — | — |
| Stockholders Equity | $8.65B -20.6% |
$10.90B -21.3% |
$13.85B -27.6% |
$19.12B +35.2% |
$14.14B +452.3% |
$2.56B +118.0% |
| R&D Expense | $3.13B -31.1% |
$4.54B -6.2% |
$4.84B +47.0% |
$3.29B +65.5% |
$1.99B +45.3% |
$1.37B +176.2% |
| Operating Income | -$3.07B +22.1% |
-$3.94B +6.9% |
-$4.24B -145.0% |
$9.42B -29.2% |
$13.30B +1842.6% |
-$763.00M -39.7% |
| Shares Outstanding | 394.00M +2.1% |
386.00M +1.0% |
382.00M -0.8% |
385.00M -4.5% |
403.00M +1.0% |
399.00M +18.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.02B | -45.4% | +615.5% |
| Revenue (ASC 606) | September 30, 2025 | $1.02B | -45.4% | +615.5% |
| Net Income | September 30, 2025 | -$200.00M | -1638.5% | +75.8% |
| Diluted EPS | September 30, 2025 | -$0.51 | -1800.0% | +76.1% |
| Total Assets | September 30, 2025 | $12.13B | -23.2% | +1.0% |
| Cash and Equivalents | September 30, 2025 | $1.13B | -31.1% | -11.5% |
| Stockholders Equity | September 30, 2025 | $9.33B | -21.8% | -0.7% |
| R&D Expense | September 30, 2025 | $801.00M | -29.6% | +14.4% |
| Operating Income | September 30, 2025 | -$260.00M | -271.4% | +71.3% |
| Shares Outstanding | September 30, 2025 | 391.00M | +1.6% | +0.5% |
- Moderna, Inc. reported Total Revenue of $1.94 billion for fiscal year 2025.
- Moderna, Inc. showed a decrease of -39.9% in Total Revenue compared to the prior fiscal year.
- Moderna, Inc. reported Revenue (ASC 606) of $1.94 billion for fiscal year 2025.
- Moderna, Inc. showed a decrease of -39.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Moderna, Inc. reported Net Income of -$2.82 billion for fiscal year 2025.
- Moderna, Inc. showed an increase of +20.8% in Net Income compared to the prior fiscal year.
- Moderna, Inc. reported Diluted EPS of $7.26 per share (loss) for fiscal year 2025.
- Moderna, Inc. showed an increase of +21.8% in Diluted EPS compared to the prior fiscal year.
- Moderna, Inc. reported Total Assets of $12.34 billion for fiscal year 2025.
- Moderna, Inc. showed a decrease of -12.8% in Total Assets compared to the prior fiscal year.
- Moderna, Inc. reported Cash and Equivalents of $2.60 billion for fiscal year 2025.
- Moderna, Inc. showed an increase of +34.7% in Cash and Equivalents compared to the prior fiscal year.
- Moderna, Inc. reported Long-Term Debt of $590.00 million for fiscal year 2025.
- Moderna, Inc. reported Stockholders Equity of $8.65 billion for fiscal year 2025.
- Moderna, Inc. showed a decrease of -20.6% in Stockholders Equity compared to the prior fiscal year.
- Moderna, Inc. reported R&D Expense of $3.13 billion for fiscal year 2025.
- Moderna, Inc. showed a decrease of -31.1% in R&D Expense compared to the prior fiscal year.
- Moderna, Inc. reported Operating Income of -$3.07 billion for fiscal year 2025.
- Moderna, Inc. showed an increase of +22.1% in Operating Income compared to the prior fiscal year.
- Moderna, Inc. reported Shares Outstanding of 394.00 million shares for fiscal year 2025.
- Moderna, Inc. showed an increase of +2.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: